Literature DB >> 22065791

IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells.

Hélène Le Buanec1, Marie-Lise Gougeon, Alexis Mathian, Pierre Lebon, Jean-Michel Dupont, Gabriel Peltre, Patrice Hemon, Michel Schmid, Bernard Bizzini, Thomas Künding, Arsène Burny, Armand Bensussan, Zahir Amoura, Robert C Gallo, Daniel Zagury.   

Abstract

Immune suppressive activities exerted by regulatory T-cell subsets have several specific functions, including self-tolerance and regulation of adaptive immune reactions, and their dysfunction can lead to autoimmune diseases and contribute to AIDS and cancer. Two functionally distinct regulatory T-cell subsets are currently identified in peripheral tissues: thymus-developed natural T regulatory cells (nTregs) controlling self-tolerance and antiinflammatory IL-10-secreting type 1 regulatory T cells (Tr1) derived from Ag-stimulated T cells, which regulate inflammation-dependent adaptive immunity and minimize immunopathology. We establish herein that cell contact-mediated nTreg regulatory function is inhibited by inflammation, especially in the presence of the complement C3b receptor (CD46). Instead, as with other T-cell subsets, the latter inflammatory conditions of stimulation skew nTreg differentiation to Tr1 cells secreting IL-10, an effect potentiated by IFN-α. The clinical relevance of these findings was verified in a study of 152 lupus patients, in which we showed that lupus nTreg dysfunction is not due to intrinsic defects but is rather induced by C3b stimulation of CD46 and IFN-α and that these immune components of inflammation are directly associated with active lupus. These results provide a rationale for using anti-IFN-α Ab immunotherapy in lupus patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065791      PMCID: PMC3223453          DOI: 10.1073/pnas.1113301108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Stability of the regulatory T cell lineage in vivo.

Authors:  Yuri P Rubtsov; Rachel E Niec; Steven Josefowicz; Li Li; Jaime Darce; Diane Mathis; Christophe Benoist; Alexander Y Rudensky
Journal:  Science       Date:  2010-09-24       Impact factor: 47.728

Review 2.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

Review 3.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Authors:  R H Schwartz
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

Review 4.  Acquisition of immunologic self-tolerance.

Authors:  R H Schwartz
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

5.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

6.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

7.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

8.  The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.

Authors:  C H P Wouters; C Diegenant; J L Ceuppens; H Degreef; E A M Stevens
Journal:  Br J Dermatol       Date:  2004-04       Impact factor: 9.302

9.  Interleukin-2 is essential for CD4+CD25+ regulatory T cell function.

Authors:  Maurus de la Rosa; Sascha Rutz; Heike Dorninger; Alexander Scheffold
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

Review 10.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07
View more
  18 in total

Review 1.  Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance.

Authors:  Hanyu Zeng; Rong Zhang; Boquan Jin; Lihua Chen
Journal:  Cell Mol Immunol       Date:  2015-06-08       Impact factor: 11.530

Review 2.  Immune Cell Metabolism in Systemic Lupus Erythematosus.

Authors:  Seung-Chul Choi; Anton A Titov; Ramya Sivakumar; Wei Li; Laurence Morel
Journal:  Curr Rheumatol Rep       Date:  2016-11       Impact factor: 4.592

Review 3.  Complement modulation of T cell immune responses during homeostasis and disease.

Authors:  Elizabeth V Clarke; Andrea J Tenner
Journal:  J Leukoc Biol       Date:  2014-09-10       Impact factor: 4.962

4.  Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.

Authors:  M Kathryn Liszewski; Martin Kolev; Gaelle Le Friec; Marilyn Leung; Paula G Bertram; Antonella F Fara; Marta Subias; Matthew C Pickering; Christian Drouet; Seppo Meri; T Petteri Arstila; Pirkka T Pekkarinen; Margaret Ma; Andrew Cope; Thomas Reinheckel; Santiago Rodriguez de Cordoba; Behdad Afzali; John P Atkinson; Claudia Kemper
Journal:  Immunity       Date:  2013-12-05       Impact factor: 31.745

Review 5.  Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets.

Authors:  Jens Geginat; Giulia Nizzoli; Moira Paroni; Stefano Maglie; Paola Larghi; Steve Pascolo; Sergio Abrignani
Journal:  Front Immunol       Date:  2015-10-13       Impact factor: 7.561

6.  Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells.

Authors:  Emily Loison; Béatrice Poirier-Beaudouin; Valérie Seffer; Audrey Paoletti; Vered Abitbol; Eric Tartour; Odile Launay; Marie-Lise Gougeon
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

7.  Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma.

Authors:  Hui Ye; Jiansong Tong; Jianzhang Wu; Xia Xu; Shenjie Wu; Botao Tan; Mengjing Shi; Jianguang Wang; Weibo Zhao; Heng Jiang; Sha Jin
Journal:  Int J Nanomedicine       Date:  2014-09-22

8.  Induction of type I and type III interferons by Borrelia burgdorferi correlates with pathogenesis and requires linear plasmid 36.

Authors:  Michelle A Krupna-Gaylord; Dionysios Liveris; Andrea C Love; Gary P Wormser; Ira Schwartz; Mary M Petzke
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

Review 9.  The complement system in glioblastoma multiforme.

Authors:  T A M Bouwens van der Vlis; J M Kros; D A M Mustafa; R T A van Wijck; L Ackermans; P M van Hagen; P J van der Spek
Journal:  Acta Neuropathol Commun       Date:  2018-09-12       Impact factor: 7.801

Review 10.  The Proportion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus: A Meta-Analysis.

Authors:  Sheng-Xiao Zhang; Xiao-Wen Ma; Yu-Feng Li; Na-Ling Lai; Ze-Hao Huang; Kai Fan; Cai-Hong Wang; Xiao-Feng Li
Journal:  J Immunol Res       Date:  2018-09-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.